Brentuximab-Vedotin (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Brentuximab-Vedotin" in German language version.

refsWebsite

Global rank German rank

8nih.gov

4^th place

7^th place

3bloodjournal.org

low place

2europa.eu

68^th place

29^th place

2ascopubs.org

low place

1fda.gov

447^th place

751^st place

1orpha.net

3,537^th place

429^th place

1g-ba.de

low place

1,618^th place

1dgho.de

low place

1awmf.org

5,401^st place

312^th place

1nejm.org

2,374^th place

1,391^st place

1hematologylibrary.org

low place

1seagen.com

low place

ascopubs.org

jco.ascopubs.org

awmf.org

Hodgkin-Lymphom. S3-Leitlinie Diagnostik, Therapie und Nachsorge von erwachsenen Patienten Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) 2013.

bloodjournal.org

dgho.de

DGHO, Bewertung (PDF; 77 kB).

europa.eu

ema.europa.eu

European Medicines Agency: European Public Assessment Report (EPAR) for Adcetris. Abgerufen am 7. März 2022.
European Medicines Agency: Zusammenfassung der Merkmale des Arzneimittels. Dezember 2021, abgerufen am 7. März 2022. (PDF; 993 kB)

fda.gov

FDA News Release vom 19. August 2011.

g-ba.de

G-BA, Beschlusstext Brentuximab Vedotin.

hematologylibrary.org

bloodjournal.hematologylibrary.org

Rothe A et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012; 120: 1470–2, PMID 22786877.

nejm.org

Younes A et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363: 1812–21, PMID 21047225.

nih.gov

ncbi.nlm.nih.gov

Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30: 631–7, PMID 22781692.
Younes A et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363: 1812–21, PMID 21047225.
Younes A et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol 2012; 30: 2183–9, PMID 22454421.
Pro B et al. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol 2012; 30: 2190–6, PMID 22614995.
Rothe A et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012; 120: 1470–2, PMID 22786877.
Chen R et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128: 1562-6, PMID 27432875.
Moskowitz CH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853-62, PMID 25796459.
Wagner-Johnston ND et al. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 2012; 53: 2283-6, PMID 22424602.

orpha.net

Orphanet: Marktzulassung mit Orphan-Drug-Designation - Europa. Abgerufen am 7. März 2022.

seagen.com

investor.seagen.com

Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma. investor.seagen.com, 19. Juni 2013, abgerufen am 11. April 2023 (englisch). Pressemitteilung von Takeda and Seattle Genetics